Fuan Pharmaceutical Gains Full Control of JD Capital-invested Team Pharmaceutical

2015-03-25

In November 2014, Fuan Pharmaceutical (Group) Co., Ltd. (300194) announced its plan to acquire 100% of JD Capital-invested Team Pharmaceutical with proceeds from private placement and cash; the total consideration would be around 570 million yuan. The deal was recently approved by the China Securities Regulatory Commission (CSRC).Wis九鼎投资(600053.SH)_上交所私募股权投资领域上市公司

Team Pharmaceutical is a manufacturer of modern pharmaceutical chemicals. It is mainly engaged in the R&D, production and sales of bulk pharmaceutical chemicals (BPC) and preparations such as antineoplastics, auxiliary drugs and drugs for respiratory diseases. As a well-known brand in clinical application, the company owns multiple exclusive and independent-pricing antineoplastics and relevant auxiliary drugs.Wis九鼎投资(600053.SH)_上交所私募股权投资领域上市公司

Fuan Pharmaceutical focuses on the R&D, production and sales of antibiotic BPC and preparations. It has established a complete industrial chain covering medical intermediate, BPC and preparations. After the acquisition, as a wholly-owned subsidiary of Fuan, Team will enrich Fuan’s existing product pipeline and strengthen its core competitiveness in pharmaceutical industry.Wis九鼎投资(600053.SH)_上交所私募股权投资领域上市公司

In recent years, as domestic consumption grows and the population ages, the pharmaceutical market keeps expanding on a yearly basis. The acquisition is a positive complementation for both sides, offering new profitable areas for public companies.Wis九鼎投资(600053.SH)_上交所私募股权投资领域上市公司

JD Capital bought shares of Team Pharmaceutical in 2012. It was the second largest shareholder of the company, holding 20% of its stakes prior to the acquisition.Wis九鼎投资(600053.SH)_上交所私募股权投资领域上市公司


Wis九鼎投资(600053.SH)_上交所私募股权投资领域上市公司

EN | CN